TY - JOUR
AU - J. E. M. O'Donnell
AU - T. D. Walters
AU - E. I. Benchimol
A1 - 
AB - INTRODUCTION: The management of pediatric inflammatory bowel disease (PIBD) has drastically changed in the last decade. The limited availability of new biologics or small molecule therapies, and concerns about durability in children has necessitated the development of other advances in management to optimize care. AREAS COVERED: This review covers guidance for management targets and advances in optimizing biologic therapies, new medical therapies, adjuvant therapies, precision medicine and mental health concerns in PIBD. This review focused on recent advances and was not intended as a complete overview of the investigations and management of pediatric IBD. EXPERT OPINION: Advancements include standardization of treatment goals via a treat-to-target strategy, optimizing anti-TNF biologics through combination therapy or proactive drug monitoring, earlier initiation of treatment for Crohn's disease, the emergence of new biologic/advanced therapies and a growing focus on adjuvant therapies targeting the microbiome. Future progress relies on the inclusion of children/adolescents in clinical trials to facilitate faster regulatory approval for pediatric therapies and the integration of precision medicine and mental health screening to improve patient care and outcomes.
AD - SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Canada.; Department of Paediatrics, University of Toronto, Toronto, Canada.; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.; Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children, Toronto, Canada.; ICES, Toronto, Canada.
AN - 39688852
BT - Expert Rev Gastroenterol Hepatol
C5 - Healthcare Disparities
CP - 12
DA - Dec
DO - 10.1080/17474124.2024.2444555
DP - NLM
ET - 20241223
IS - 12
JF - Expert Rev Gastroenterol Hepatol
LA - eng
N2 - INTRODUCTION: The management of pediatric inflammatory bowel disease (PIBD) has drastically changed in the last decade. The limited availability of new biologics or small molecule therapies, and concerns about durability in children has necessitated the development of other advances in management to optimize care. AREAS COVERED: This review covers guidance for management targets and advances in optimizing biologic therapies, new medical therapies, adjuvant therapies, precision medicine and mental health concerns in PIBD. This review focused on recent advances and was not intended as a complete overview of the investigations and management of pediatric IBD. EXPERT OPINION: Advancements include standardization of treatment goals via a treat-to-target strategy, optimizing anti-TNF biologics through combination therapy or proactive drug monitoring, earlier initiation of treatment for Crohn's disease, the emergence of new biologic/advanced therapies and a growing focus on adjuvant therapies targeting the microbiome. Future progress relies on the inclusion of children/adolescents in clinical trials to facilitate faster regulatory approval for pediatric therapies and the integration of precision medicine and mental health screening to improve patient care and outcomes.
PY - 2024
SN - 1747-4124
SP - 815
EP - 827+
ST - Advancements in the management of pediatric inflammatory bowel disease
T1 - Advancements in the management of pediatric inflammatory bowel disease
T2 - Expert Rev Gastroenterol Hepatol
TI - Advancements in the management of pediatric inflammatory bowel disease
U1 - Healthcare Disparities
U3 - 10.1080/17474124.2024.2444555
VL - 18
VO - 1747-4124
Y1 - 2024
ER -